Most Dutch universities run technology transfer the way most European universities do: a small office embedded inside a single institution, handling invention disclosures, patent filings, and licensing for that institution’s own researchers. Oncode Institute breaks that pattern for one field, cancer research, by operating as an independent, cross-institutional organization that coordinates researchers and centralizes valorization strategy across thirteen partner institutes rather than sitting inside any one of them. Comparing the two shows what a decentralized national tech-transfer system can gain, and give up, by building a domain-specific layer on top of it.
How technology transfer works at Dutch universities
Nearly every Dutch academic institution runs its own technology transfer office (TTO), typically as a unit inside the university’s or university medical center’s (UMC) own research administration, though several institutions route the legal and commercial side of that work through a separate holding company rather than the university itself. Utrecht University and UMC Utrecht, for example, jointly operate Utrecht Holdings — legally two entities, UU Holding B.V. and UMC Utrecht Holding B.V. — established in 1998 to file patents, negotiate licenses, and take equity stakes in spin-off companies on behalf of the two institutions. That holding-company structure is common in the Netherlands: it keeps commercial activity, including equity ownership in startups, in a separate legal entity from the tax-exempt academic institution, which simplifies liability, tax treatment, and the eventual sale or transfer of an equity stake. It does not, on its own, make the office bigger or less tied to its home institution — the holding company still serves one university (or one university-UMC pair), the same way an in-house office would.
The Association of Technology Transfer Professionals (ASTP), the European professional body most Dutch TTO staff are affiliated with, and the KWF Kankerbestrijding (Dutch Cancer Society) directory of Dutch TTOs and valorization contacts both confirm the same underlying picture: technology transfer in the Netherlands is organized institution by institution, with each university, UMC, or applied-research institute maintaining its own office (whether structured in-house or through a holding B.V.) rather than any single national body handling licensing and commercialization across the sector. This is the same decentralized, university-owned pattern seen in the U.S. TLO model (see CASRAI’s Technology Licensing Office (TLO) entry) and contrasts with more centralized regional or sector-wide structures elsewhere — including, within the Netherlands’ own borders, Oncode Institute itself.
Why Dutch TTOs are typically described as small and risk-averse
The OECD’s standard definition of a technology transfer office — “organisational structures whose common core role is to assist public research organisations in managing their intellectual assets in ways that facilitate their transformation into benefits for society” — applies to Dutch offices as much as any other country’s, but the scale at which Dutch TTOs operate is a direct consequence of the one-office-per-institution model above: each office serves a single university’s or UMC’s invention flow, which for all but the largest technical universities and academic medical centers is a modest number of disclosures per year. Academic research comparing Dutch university technology-transfer performance (published in The Journal of Technology Transfer) has found meaningful variation in output across Dutch institutions, with the technical universities and academic medical centers generally showing stronger commercialization metrics than the general research universities — consistent with an office’s scale and the surrounding institution’s disclosure volume, rather than a single national TTO “model,” driving performance.
A small, single-institution office also tends toward risk-averse patent and licensing decisions almost by structural necessity: with a limited discretionary budget for external patent counsel and prosecution costs, and no dedicated function for a specific, capital-intensive research area, an in-house TTO has to be selective about which disclosures receive outside patent counsel and which are triaged out. That triage logic — the same “invention disclosure and assessment” workflow AUTM (the Association of University Technology Managers) uses to teach TTO operations generally — is standard practice everywhere a TTO runs on institutional overhead rather than a dedicated commercialization budget for one field. It is one of the structural gaps a field-specific, cross-institutional body like Oncode Institute is positioned to address for oncology research specifically, by pooling scale that no single Dutch university’s own TTO has on its own.
Oncode Institute: an independent, cross-institutional alternative
Oncode Institute is a Dutch nonprofit research and valorization organization dedicated specifically to fundamental and translational cancer research. It was formally launched on 5 February 2018, following a 2015 memorandum of understanding among Dutch oncology research leaders and KWF Kankerbestrijding (the Dutch Cancer Society) to build a shared national structure for cancer-research translation rather than leaving it to each institution’s own resources. As of its own published figures, Oncode coordinates more than 700 researchers across thirteen partner institutes, including Amsterdam UMC, Erasmus MC, Leiden University and Leiden UMC, the Netherlands Cancer Institute (NKI), Princess Máxima Center, Radboud University and Radboudumc, UMC Groningen, UMC Utrecht and Utrecht University, Sanquin, AMOLF, and the Hubrecht Institute. It is funded by KWF, the Dutch government (the Ministries of Economic Affairs and Climate, Education Culture and Science, and Health Welfare and Sport via ZonMw), and the Health~Holland public-private life-sciences partnership — not by any single university’s own budget.
Structurally, Oncode does not own or replace the researchers’ home institutions: participating scientists remain employed by their own university, UMC, or institute, and Oncode describes its approach as building “a network, not buildings.” What it centralizes instead is scientific leadership, a shared “Oncode-PoC” proof-of-concept and Valorisation Strategy function, and cross-institutional coordination for translating oncology findings toward diagnostics and treatments — a valorization capability most individual Dutch TTOs could not sustain on their own for a single research domain. Critically, Oncode functions as a layer on top of the existing institutional structures rather than a full replacement for them: when Oncode-affiliated research reaches a licensing deal, the institution’s own tech-transfer entity is typically still party to it. A 2024 license agreement between diagnostics company SkylineDx, Oncode Institute, and Utrecht Holdings for a prognostic algorithm is a documented example — Oncode and the host institution’s own holding company co-signed the deal, rather than Oncode transacting alone.
A related but distinct entity, Oncode Accelerator, launched later as a separately funded, EU-backed program focused specifically on advancing early oncology discoveries toward pharma- and biotech-ready assets — a further degree of specialization built on top of Oncode Institute’s own network, illustrating how far this model has moved from the single-institution TTO baseline.
Oncode vs. the standard in-house TTO model
- Institutional scope. A standard Dutch university TTO (in-house or holding-company-structured) serves one institution’s full invention portfolio, across every discipline. Oncode serves one research domain, cancer, across thirteen institutions at once.
- Governance and ownership. A university TTO or holding B.V. is owned by, and reports into, its single home institution. Oncode is an independent nonprofit governed separately from any one university, funded primarily by a disease-focused charity (KWF) and government ministries rather than one institution’s operating budget.
- Scale of the valorization function. Because a standard TTO’s disclosure volume is bounded by one institution’s output, it typically cannot justify a dedicated, field-specialized commercialization team. Oncode pools disclosure volume and scientific leadership across thirteen institutes specifically to sustain that kind of dedicated function for oncology.
- Relationship to existing structures. Oncode does not dissolve or replace each partner institute’s own TTO or holding company — it adds a coordinating, domain-specific layer, and license agreements (like the SkylineDx deal above) can still involve both Oncode and the host institution’s own tech-transfer entity.
- Comparable international pattern. The closest analogue elsewhere in this series is France’s regional SATT network, which also centralizes tech-transfer activity across multiple universities in a defined scope — geographic region rather than research domain — instead of leaving it to each university alone. See CASRAI’s guide to France’s SATT network for the comparison.
What this means for research administrators and other institutions
For a research administrator evaluating the Dutch system, or considering whether a similar structure could work elsewhere, the Oncode model is best understood as evidence for a narrower claim than “the Netherlands has moved away from in-house tech transfer.” Most Dutch technology transfer, across every field outside oncology, still runs through the standard single-institution office or holding-company structure described above. What Oncode demonstrates is that a decentralized national system can still support a centralized, field-specific commercialization layer when a disease-focused funder (here, KWF) and government co-funding are willing to underwrite the coordination cost across institutions — without requiring any partner university to give up its own TTO. That is a meaningfully different design question from choosing a single national TTO model outright, and it is the reason Oncode is worth studying as a distinct structure rather than as a simple substitute for the standard university TTO covered elsewhere in CASRAI’s technology transfer coverage (see the technology transfer process guide and how TTOs evaluate and price a license).
The Netherlands in CASRAI’s international tech-transfer-models series
This guide is part of an ongoing series comparing how different countries structure the movement of publicly funded research into practical use. See also:
- The Fraunhofer-Gesellschaft Model: How Germany Structures Applied-Research Technology Transfer — a funding-formula-driven applied-research network, distinct from university-based transfer.
- France’s SATT Network: How Regional Companies Centralize University Tech Transfer — the closest structural parallel to Oncode’s cross-institutional pooling, organized by region instead of research domain.
- Taiwan’s ITRI vs. Singapore’s A*STAR: Government Research Institute Tech Transfer Models — government research institutes as a third structural alternative to the university TTO.
- Australia’s University Technology Transfer Model — CSIRO spinouts and university venture funds alongside the standard TTO.
- EU-Wide Technology Transfer Coordination — how ASTP and the Knowledge Valorisation Platform coordinate across national systems like the Netherlands’.
For the underlying vocabulary used throughout this series, see CASRAI’s Technology Transfer and Technology Licensing Office (TLO) dictionary entries, and the Technology Transfer & Innovation pillar page for the cluster’s full scope.
Frequently asked questions
Is Oncode Institute a university?
No. Oncode Institute is an independent Dutch nonprofit organization. Its affiliated researchers remain employed by their home university, UMC, or research institute; Oncode coordinates scientific leadership, funding, and valorization strategy across those thirteen partner institutions rather than employing researchers or granting degrees itself.
Does Oncode replace the technology transfer offices at its partner universities?
No. Partner institutions keep their own TTOs or holding companies, and those entities can still be party to licensing deals involving Oncode-affiliated research, as in the documented SkylineDx/Oncode Institute/Utrecht Holdings license agreement. Oncode adds a coordinating, oncology-specific layer on top of the existing structures rather than replacing them.
Why don’t more Dutch universities have larger, centralized TTOs like Oncode’s?
Oncode’s scale is possible because a disease-focused funder (KWF Kankerbestrijding) and Dutch government ministries chose to underwrite a shared, cross-institutional structure specifically for cancer research. Extending that model to every research field would require a comparable dedicated funder and coordination mechanism for each domain, which does not currently exist for most other fields in the Netherlands — most Dutch technology transfer outside oncology still runs through the standard single-institution office model.
What is a “holding B.V.” and why do some Dutch universities use one?
A holding B.V. (besloten vennootschap, a Dutch private limited company) is a separate legal entity a university or UMC sets up to handle commercial activity — patent licensing and equity stakes in spin-off companies — apart from the tax-exempt academic institution itself. Utrecht Holdings (UU Holding B.V. and UMC Utrecht Holding B.V.), established in 1998, is a documented example. The holding structure changes the legal and tax mechanics of commercialization; it does not, by itself, change which institution the office serves.
